The US  Food and Drug Administration  has accepted  Wyeth Pharmaceuticals’s  supplemental new drug application for the treatment of patients with community-acquired pneumonia (CAP).

The US  Food and Drug Administration  has accepted  Wyeth Pharmaceuticals’s  supplemental new drug application for its first-in-class antibiotic Tygacil for the treatment of patients with community-acquired pneumonia, or CAP. The company said the SNDA submission included integrated data from two investigational clinical studies that included 846 patients. According to the company’s study data Tygacil cured 89.7% of patients hospitalized with CAP. The most common adverse events for Tygacil were nausea, vomiting and abdominal pain, the company said.